COMMUNIQUÉS West-GlobeNewswire

-
Trading by management and close relations of management
02/02/2024 -
Jasper Therapeutics, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
02/02/2024 -
Pixium Vision announces the rejection of the sale plan (plan de cession) by the Court and the conversion of the receivership proceedings into liquidation proceedings
02/02/2024 -
Pixium Vision annonce le rejet du plan de cession par le Tribunal et la conversion de la procédure de redressement judiciaire en liquidation judiciaire
02/02/2024 -
Vera Therapeutics to Participate in the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference
02/02/2024 -
Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
02/02/2024 -
GRI Bio Announces Pricing of $5.5 Million Public Offering
02/02/2024 -
SAB Biotherapeutics Announces Executive Leadership Change
02/02/2024 -
Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
02/02/2024 -
BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
02/02/2024 -
Orchard Therapeutics Announces Multiple Presentations at the 20th Annual WORLDSymposium
02/02/2024 -
Sio Gene Therapies, Inc. to File for Dissolution and Declare an Initial Liquidating Distribution of $0.435 Per Share
02/02/2024 -
Agios to Webcast Conference Call of Fourth Quarter and Year End 2023 Financial Results on February 15, 2024
02/02/2024 -
BridgeBio Pharma Shares Positive Results of Single-Arm Phase 3 Study of Acoramidis in Japanese Patients with Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Including No Mortality Reported in the Trial at 30 Months
02/02/2024 -
Eton Pharmaceuticals Announces Commercial Availability of Ultra-Rare Disease Product Nitisinone Capsules
02/02/2024 -
Tisotumab Vedotin Marketing Authorization Application Validated by European Medicines Agency for Treatment of Recurrent or Metastatic Cervical Cancer
02/02/2024 -
Regeneron Reports Fourth Quarter and Full Year 2023 Financial and Operating Results
02/02/2024 -
Linvoseltamab Receives EMA Filing Acceptance for Treatment of Relapsed/Refractory Multiple Myeloma
02/02/2024 -
HUTCHMED Announces that Inmagene Exercises Option to License Two Drug Candidates as Part of Strategic Partnership
02/02/2024
Pages